Radiotheranostics Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others), By Application (Oncology v/s Non-Oncology), By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others) and Region

Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format

View Details Buy Now 2890 Download Sample Ask for Discount Request Customization

Radiotheranostics Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others), By Application (Oncology v/s Non-Oncology), By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others) and Region

Global radiotheranostics market is anticipated to register growth at an impressive CAGR in the forecast period, 2023-2027. Radiotheranostics is a process that involves the use of radionuclides for paired imaging and therapy agents. It is a systematic integration of targeted diagnostics and therapeutics. The growing prevalence of cancer and the rising adoption of injectable radiopharmaceuticals that have antitumor effects are majorly contributing to the global radiotheranostics market growth. The increasing usage of radiotheranostics in cancer diagnosis and management is providing a thrust to the market. Radiotheranostics have enhanced therapy efficacy, the ability to manage adverse and critical health situations, which results in improved patient outcomes.

Moreover, the recent research and developments in the radiotheranostics field is creating a positive impact to the market growth. For instance, there have been major outcomes in radiotheranostics for prostate cancer and neuroendocrine tumors. Additionally, the regulatory approval of numerous radiotheranostics pairs is expected to boost their adoption for cancer treatments. For instance, the approvals of new radiotheranostics agents such as 177Lu-PSMA-617 and 177Lu-DOTATATE have resulted in the resurgence of research in the field of radiotheranostics and have proliferated the number of clinical trials and testing several other novel radiotheranostics. Furthermore, the continuous support in research and development to keep pace with current momentum in radiotheranostics innovations is supporting the market growth. Additionally, the clinical use of radiotheranostics agents have increased dramatically due to the successful strides that have been made in the understanding of underlying biology of cancer and enhanced methods for synthesizing and designing targeted theragnostic agents. This, in turn, is positively influencing the market growth.

Structural imaging is the most crucial component of staging, diagnosing, and assessing responses in cancer patients. However, patients and healthcare professionals are increasingly seeking non-invasive methods of investigating tumour phenotypes and assessing molecular and functional responses to therapy. Therefore, radiotheranostics, a combination of non-invasive diagnostic imaging with targeted therapy, is widely being implemented. As a result, the global market for radiotheranostics is anticipated to propel at a rapid pace in the coming years.

DOWNLOAD FREE SAMPLE REPORT

Market Segmentation

The global radiotheranostics market is segmented by radioisotope, application, end user, competitive landscape, and regional distribution.

Company Profile

TransCode Therapeutics, Inc., Curium SAS, GE Healthcare Inc., Bayer AG, Lantheus Medical, Imaging, Inc., Novartis AG, Spectrum Pharmaceuticals, Inc., Ipsen S.A., Actinium Pharmaceuticals, Inc. (ATNM), Nordic Nanovector ASA, Y-mAbs Therapeutics, Inc., Sofie Biosciences, Inc., Terumo Corporation, Sirtex Medical Limited, and Boston Scientific Corporation are the leading market players responsible for the growth of global radiotheranostics market.

Attribute

Details

Base Year

2021

Historical Data

2017 â€“ 2020

Estimated Year

2022

Forecast Period

2023 – 2027

Quantitative Units

Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments covered

·         Radioisotope

·         Application

·         End User

Regional scope

North America, Europe, Asia Pacific, Middle east and Africa, South America

Key companies profiled

TransCode Therapeutics, Inc., Curium SAS, GE Healthcare Inc., Bayer AG, Lantheus Medical, Imaging, Inc., Novartis AG, Spectrum Pharmaceuticals, Inc., Ipsen S.A., Actinium Pharmaceuticals, Inc. (ATNM), Nordic Nanovector ASA, Y-mAbs Therapeutics, Inc., Sofie Biosciences, Inc., Terumo Corporation, Sirtex Medical Limited, and Boston Scientific Corporation

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Table of Content

To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )

List Tables Figures

To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )

FAQ'S

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@marketinsightsresearch.com

Within 24 to 48 hrs.

You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.